NCT02465866View on ClinicalTrials.gov

A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

CL-108

Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth

DRUG

Vicoprofen

Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth

DRUG

Ultracet

Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth

DRUG

Phenergan

Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth

Sponsors
All Listed Sponsors
lead

Charleston Laboratories, Inc

INDUSTRY

NCT02465866 - A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions | Biotech Hunter | Biotech Hunter